Cancer Archive

Two prostate cancer survivors talk about the importance of prostate cancer education among African Americans and other men at high risk.

Ken Gannon talks about his 13 year battle with prostate cancer and his experiences with second-line hormone therapies, investigational drugs, and four clinical trials, one of which nearly killed him.

Patient Ben Hunter explains why he decided to postpone treatment for prostate cancer and the lifestyle changes he made immediately following his diagnosis.

Patient Jeffrey Caruso explains why he decided to pursue active surveillance and under what circumstances he would opt to treat his prostate cancer.

How endorectal MRI helped one couple choose the “best” treatment for prostate cancer.

After talking with numerous medical professionals and asking friends about how they treated their prostate cancers, financial services executive Steve Henley opted to have a robotic-assisted laparoscopic prostatectomy. In this interview, he explains what factors went into that decision.

Given the beneficial effects and the lack of a survival difference, intermittent hormone therapy may be a preferred regimen for men with advanced prostate cancer.

High levels of selenium in the blood are associated with a slightly higher-than-normal risk of aggressive prostate cancer.

A European study finds that mortality is higher among men who pursue hormone therapy for just six months. But the study was conducted in men with relatively large tumors, not small, early-stage tumors, the kind found most often in American men.

According to a 2007 Swedish study, a PSA test done between the ages of 44 and 50 may predict whether or not a man will develop prostate cancer later in life.